Immunome (NASDAQ:IMNM) Price Target Raised to $40.00

by · The Cerbat Gem

Immunome (NASDAQ:IMNM – Free Report) had its price objective increased by Evercore ISI from $18.00 to $40.00 in a report released on Tuesday morning, Marketbeat Ratings reports. They currently have an outperform rating on the stock.

Other research analysts have also recently issued research reports about the company. Stephens raised their price target on Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a research report on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. The Goldman Sachs Group began coverage on shares of Immunome in a research report on Monday, September 22nd. They issued a “buy” rating and a $26.00 target price for the company. Leerink Partners set a $40.00 price target on shares of Immunome in a research report on Monday. Finally, Truist Financial assumed coverage on shares of Immunome in a research note on Monday, December 1st. They issued a “buy” rating and a $36.00 price objective on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.09.

Read Our Latest Stock Analysis on Immunome

Immunome Trading Up 0.9%

Shares of IMNM opened at $19.95 on Tuesday. Immunome has a 12 month low of $5.15 and a 12 month high of $25.30. The firm’s 50 day moving average is $17.53 and its 200-day moving average is $12.60. The stock has a market capitalization of $1.83 billion, a PE ratio of -6.76 and a beta of 2.17.

Immunome (NASDAQ:IMNM – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Equities research analysts predict that Immunome will post -2.21 earnings per share for the current fiscal year.

Insider Activity at Immunome

In other news, CEO Clay B. Siegall acquired 46,511 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average price of $21.50 per share, with a total value of $999,986.50. Following the acquisition, the chief executive officer directly owned 853,247 shares in the company, valued at $18,344,810.50. The trade was a 5.77% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.69% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. MetLife Investment Management LLC lifted its holdings in shares of Immunome by 19.1% during the first quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock worth $285,000 after purchasing an additional 6,792 shares during the period. Tema Etfs LLC bought a new position in Immunome during the 2nd quarter worth $1,074,000. Kennedy Capital Management LLC grew its position in shares of Immunome by 642.6% in the 2nd quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock valued at $1,017,000 after buying an additional 94,627 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Immunome by 55.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock valued at $5,216,000 after buying an additional 275,000 shares during the period. Finally, Intech Investment Management LLC raised its position in shares of Immunome by 17.8% during the second quarter. Intech Investment Management LLC now owns 40,565 shares of the company’s stock worth $377,000 after acquiring an additional 6,141 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

About Immunome

(Get Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Recommended Stories